Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

Clinical trial NCT06133972 · RECRUITING

Trial details

NCT number: NCT06133972
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Systemic Lupus Erythematosus

Start date: 2024-05-21
Primary completion: 2030-04-08
Enrollment: 550

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.